Press Releases

Press Releases

  • March 2, 2021
    Aileron Therapeutics Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
  • January 11, 2021
    Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering with Participation by New Fundamental Healthcare Investors Acorn Bioventures, BVF Partners, L.P. and Maven Investment Partners
  • January 6, 2021
    Aileron Therapeutics Announces $35.9 Million Registered Direct Offering
  • December 21, 2020
    Aileron Therapeutics Provides Business Update and Outlines 2021 Strategic Priorities
  • November 12, 2020
    Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
  • October 24, 2020
    Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
  • October 20, 2020
    Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium
  • October 12, 2020
    Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium
  • September 21, 2020
    Aileron Therapeutics Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
  • September 10, 2020
    Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference